English
This article is from Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association , volume 19 . Abstract Background and Aims:: Tacrolimus is a macrolide immunosuppressant used for prevention of allograft rejection in organ transplantation and metabolized in the liver and intestine by cytochrome P450 3A4 (CYP3A4) enzyme. A single nucleotide polymorphism (SNP) in the CYP3A4 promoter region has been identified. It has been shown that the presence of CYP3A4*1B allele (variant GG) is associated with a reduced catalytic activity of CYP3A4 ,in vivo. The aim of this study was to determine the role of CYP3A4*1B on tacrolimus dosing and clinical outcome in liver transplant recipients. Subjects and Methods:: Forty-eight liver transplant recipients were stratified according to the genotype. There were 32 wild-type (AA) patients and 5 homozygous variant (GG) and 11 (AG) heterozygous. Tacrolimus doses and trough concentrations as well as phenotypic data were collected in the first 10 days of the transplant. Results:: The tacrolimus concentration was significantly higher in the wild (AA) group as compared to homozygous variant (GG) and heterozygous (AG) patients.
Sign in with your free account to read, download EPUBs or listen.
Ebook · Cytochrome P450 3A4*1B as Pharmacogenomic Predictor of Tacrolimus Pharmacokinetics and Clinical Outcome in the Liver Transplant Recipients. · Albekairy, Abdulkareem, Alkatheri, Abdulmalik, Fujita, Shiro, Hemming, Alan, Howard, Richard, Reed, Alan, Karlix, Janet · Internet Archive